TIGIT and metastatic melanoma: Interestingly, co-blockade of TIGIT and PD-1 on CD8+ T cells was recently shown to be less effective on tumor infiltrating lymphocytes as compared to circulating melanoma-specific CD8+ T cells in patients with metastatic melanoma.